- Home
- KPRX vs POAI Comparison
KPRX vs POAI Comparison
Compare KPRX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- POAI
- Stock Information
- Founded
- KPRX 1998
- POAI 2002
- Country
- KPRX United States
- POAI United States
- Employees
- KPRX N/A
- POAI N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- POAI Industrial Specialties
- Sector
- KPRX Health Care
- POAI Health Care
- Exchange
- KPRX Nasdaq
- POAI Nasdaq
- Market Cap
- KPRX 8.3M
- POAI 8.9M
- IPO Year
- KPRX N/A
- POAI N/A
- Fundamental
- Price
- KPRX $3.13
- POAI $1.10
- Analyst Decision
- KPRX Strong Buy
- POAI Hold
- Analyst Count
- KPRX 1
- POAI 1
- Target Price
- KPRX $10.00
- POAI N/A
- AVG Volume (30 Days)
- KPRX 12.7K
- POAI 82.2K
- Earning Date
- KPRX 05-09-2025
- POAI 05-15-2025
- Dividend Yield
- KPRX N/A
- POAI N/A
- EPS Growth
- KPRX N/A
- POAI N/A
- EPS
- KPRX N/A
- POAI N/A
- Revenue
- KPRX $20,000.00
- POAI $1,623,817.00
- Revenue This Year
- KPRX N/A
- POAI $486.27
- Revenue Next Year
- KPRX N/A
- POAI $65.50
- P/E Ratio
- KPRX N/A
- POAI N/A
- Revenue Growth
- KPRX N/A
- POAI N/A
- 52 Week Low
- KPRX $2.51
- POAI $0.55
- 52 Week High
- KPRX $5.55
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- KPRX 42.15
- POAI 50.57
- Support Level
- KPRX $2.85
- POAI $0.85
- Resistance Level
- KPRX $3.30
- POAI $1.19
- Average True Range (ATR)
- KPRX 0.20
- POAI 0.09
- MACD
- KPRX -0.02
- POAI 0.01
- Stochastic Oscillator
- KPRX 16.34
- POAI 42.74
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.